Cutler Group LP Denali Therapeutics Inc. Call Options Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Oct 25, 2022	BUY	$25.97 - $38.53 $36,358 - $53,942	1,400 New	1,400 $2,000
Q1 2022 Apr 14, 2022	BUY	$29.0 - $47.27 $5,800 - $9,454	200 Added 40.0%	700 $1,000
Q4 2021 Jan 18, 2022	SELL	$42.59 - $55.02 $119,252 - $154,056	-2,800 Reduced 84.85%	500 $0
Q3 2021 Oct 26, 2021	BUY	$48.48 - $78.23 $43,632 - $70,407	900 Added 37.5%	3,300 $6,000
Q2 2021 Jul 19, 2021	BUY	$50.3 - $78.44 $85,510 - $133,348	1,700 Added 242.86%	2,400 $40,000
Q1 2021 Apr 26, 2021	SELL	$53.8 - $81.53 $317,420 - $481,027	-5,900 Reduced 89.39%	700 $2,000
Q4 2020 Jan 21, 2021	BUY	$36.89 - $93.56 $166,005 - $421,020	4,500 Added 214.29%	6,600 $180,000
Q3 2020 Oct 27, 2020	BUY	$23.13 - $38.84 $46,260 - $77,680	2,000 Added 2000.0%	2,100 $9,000
Q1 2020 May 07, 2020	BUY	$14.2 - $27.98 $1,420 - $2,798	100 New	100 $0

228

120M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.24B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.